Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6)

on behalf of the ELM-2 Investigators

doi:10.1038/s43018-025-00967-6

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6)

on behalf of the ELM-2 Investigators

Medical Oncology

Sungkyunkwan University
Seoul National University
The Catholic University of Korea
Hospital Universitario La Fe
Medical University of Łódź
National University Hospital
University of Melbourne
Tianjin Medical University
Fudan University
Zhengzhou University
The First Affiliated Hospital of Zhengzhou University
Centre Hospitalier Universitaire de Nantes
Dong-A University
Singapore General Hospital
Vall d'Hebron Institute of Oncology
Koo Foundation Sun Yat-Sen Cancer Center
University of Iowa
Hospital Universitario Son Espases
Regeneron Pharmaceuticals, Inc.
Ltd.
Maria Sklodowska-Curie Institute of Oncology
Tufts Medical Center
University of Texas Southwestern Medical Center
Kosair Children's Hospital
Wake Forest University
Mayo Clinic Rochester, MN
Beth Israel Deaconess Medical Center
Rush University Medical Center
Hackensack Meridian Health
Cleveland Clinic Foundation
OU Health-Stephenson Cancer Center
Cornell University
Cardiff & Vale University Health Board
University Hospitals Plymouth NHS Trust
Royal Cornwall Hospitals NHS Trust
King’s College Hospital
Royal Marsden NHS Foundation Trust
Chang Gung Memorial Hospital
National Taiwan University
China Medical University Taichung
National Cheng Kung University
Hospital de La Santa Creu I Sant Pau
University of Barcelona
Hospital Clínic de Barcelona

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

Correction to: Nature Cancerhttps://doi.org/10.1038/s43018-025-00921-6, published online 17 March 2025.

Original language	English
Pages (from-to)	907
Number of pages	1
Journal	Nature Cancer
Volume	6
Issue number	5
DOIs	https://doi.org/10.1038/s43018-025-00967-6
State	Published - May 2025

Access to Document

10.1038/s43018-025-00967-6

Fingerprint

Dive into the research topics of 'Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6)'. Together they form a unique fingerprint.

Cite this

@article{ea93b913b7134ef2af57ab1b51771886,

title = "Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6)",

abstract = "Correction to: Nature Cancerhttps://doi.org/10.1038/s43018-025-00921-6, published online 17 March 2025.",

author = "\{on behalf of the ELM-2 Investigators\} and Kim, \{Won Seog\} and Kim, \{Tae Min\} and Cho, \{Seok Goo\} and Isidro Jarque and El{\.z}bieta Iskierka-Ja{\.z}d{\.z}ewska and Poon, \{Li Mei\} and Prince, \{H. Miles\} and Huilai Zhang and Junning Cao and Mingzhi Zhang and Beno{\^i}t Tessoulin and Oh, \{Sung Yong\} and Francesca Lim and Cecilia Carpio and Tan, \{Tran Der\} and Sabarish Ayyappan and Antonio Gutierrez and Jingxian Cai and Melanie Ufkin and Saleem Shariff and Jurriaan Brouwer-Visser and Aafia Chaudhry and Hesham Mohamed and Srikanth Ambati and Jan Walewski and Umar Farooq and Andreas Klein and Farrukh Awan and Don Stevens and Rakhee Vaidya and Villasboas, \{Jose C.\} and Jon Arnason and Parameswaran Venugopal and Lori Leslie and Deepa Jagadeesh and Sami Ibrahimi and Thomas Jandl and John Allan and Nagah Elmusharaf and David Lewis and David Tucker and Andrea Kuhnl and David Cunningham and Wang, \{Ming Chung\} and Wu, \{Shang Ju\} and Yeh, \{Su Peng\} and Chen, \{Tsai Yun\} and Sara Miqueleiz and Eva Gonzalez-Barca and Laura Magnano",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = may,

doi = "10.1038/s43018-025-00967-6",

language = "English",

volume = "6",

pages = "907",

journal = "Nature Cancer",

issn = "2662-1347",

number = "5",

}

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6). / on behalf of the ELM-2 Investigators.
In: Nature Cancer, Vol. 6, No. 5, 05.2025, p. 907.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Author Correction

T2 - Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6)

AU - on behalf of the ELM-2 Investigators

AU - Kim, Won Seog

AU - Kim, Tae Min

AU - Cho, Seok Goo

AU - Jarque, Isidro

AU - Iskierka-Jażdżewska, Elżbieta

AU - Poon, Li Mei

AU - Prince, H. Miles

AU - Zhang, Huilai

AU - Cao, Junning

AU - Zhang, Mingzhi

AU - Tessoulin, Benoît

AU - Oh, Sung Yong

AU - Lim, Francesca

AU - Carpio, Cecilia

AU - Tan, Tran Der

AU - Ayyappan, Sabarish

AU - Gutierrez, Antonio

AU - Cai, Jingxian

AU - Ufkin, Melanie

AU - Shariff, Saleem

AU - Brouwer-Visser, Jurriaan

AU - Chaudhry, Aafia

AU - Mohamed, Hesham

AU - Ambati, Srikanth

AU - Walewski, Jan

AU - Farooq, Umar

AU - Klein, Andreas

AU - Awan, Farrukh

AU - Stevens, Don

AU - Vaidya, Rakhee

AU - Villasboas, Jose C.

AU - Arnason, Jon

AU - Venugopal, Parameswaran

AU - Leslie, Lori

AU - Jagadeesh, Deepa

AU - Ibrahimi, Sami

AU - Jandl, Thomas

AU - Allan, John

AU - Elmusharaf, Nagah

AU - Lewis, David

AU - Tucker, David

AU - Kuhnl, Andrea

AU - Cunningham, David

AU - Wang, Ming Chung

AU - Wu, Shang Ju

AU - Yeh, Su Peng

AU - Chen, Tsai Yun

AU - Miqueleiz, Sara

AU - Gonzalez-Barca, Eva

AU - Magnano, Laura

PY - 2025/5

Y1 - 2025/5

N2 - Correction to: Nature Cancerhttps://doi.org/10.1038/s43018-025-00921-6, published online 17 March 2025.

AB - Correction to: Nature Cancerhttps://doi.org/10.1038/s43018-025-00921-6, published online 17 March 2025.

UR - https://www.scopus.com/pages/publications/105008332166

U2 - 10.1038/s43018-025-00967-6

DO - 10.1038/s43018-025-00967-6

M3 - Comment/debate

C2 - 40240622

AN - SCOPUS:105008332166

SN - 2662-1347

VL - 6

SP - 907

JO - Nature Cancer

JF - Nature Cancer

IS - 5

ER -

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this